Table of Contents

company-logo

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Dividend Announcement

• Aptose Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Aptose Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Aptose Biosciences Dividend History

Aptose Biosciences Dividend Yield

Aptose Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Aptose Biosciences stock? Use our calculator to estimate your expected dividend yield:

Aptose Biosciences Financial Ratios

P/E ratio-0.16
PEG ratio-0.01
P/B ratio-2.93
ROE-5693.38%
Payout ratio0.00%
Current ratio0.80
Quick ratio0.80
Cash Ratio0.66

Aptose Biosciences Dividend FAQ

Does Aptose Biosciences stock pay dividends?
Aptose Biosciences does not currently pay dividends to its shareholders.
Has Aptose Biosciences ever paid a dividend?
No, Aptose Biosciences has no a history of paying dividends to its shareholders. Aptose Biosciences is not known for its dividend payments.
Why doesn't Aptose Biosciences pay dividends?
There are several potential reasons why Aptose Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Aptose Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Aptose Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Aptose Biosciences a dividend aristocrat?
Aptose Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Aptose Biosciences a dividend king?
Aptose Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Aptose Biosciences a dividend stock?
No, Aptose Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Aptose Biosciences stocks?
To buy Aptose Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Aptose Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.